Drugs that contain Ritonavir
1. Norvir patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5635523 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
| US5674882 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
| US5541206 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
| US5948436 | ABBVIE | Pharmaceutical composition |
Sep, 2013
(10 years ago) | |
| US5484801 | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jan, 2014
(10 years ago) | |
|
US5674882 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
|
US5635523 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
|
US5541206 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
|
US5948436 (Pediatric) | ABBVIE | Pharmaceutical composition |
Mar, 2014
(10 years ago) | |
| US5648497 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2014
(9 years ago) | |
|
US5484801 (Pediatric) | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jul, 2014
(9 years ago) | |
|
US5648497 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2015
(9 years ago) | |
| US6037157 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
| US6703403 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
|
US6037157 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
|
US6703403 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
| US6232333 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
|
US6232333 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(6 years ago) | |
| US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
|
US7148359 (Pediatric) | ABBVIE | Polymorph of a pharmaceutical |
Jan, 2020
(4 years ago) | |
| US7141593 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
| US7432294 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
| US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7432294 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7141593 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7364752 (Pediatric) | ABBVIE | Solid dispersion pharamaceutical formulations |
May, 2021
(2 years ago) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8691878 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
|
US8399015 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
|
US8691878 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
|
US8268349 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
| US8470347 | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Sep, 2026
(2 years from now) | |
|
US8470347 (Pediatric) | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Mar, 2027
(2 years from now) | |
Market Authorisation Date: 10 February, 2010
Treatment: Use of ritonavir in combination with any reverse transcriptase inhibitor; Treatment of hiv infection in combination with other antiretroviral agents; Treatment of hiv-infection in combination with oth...
Dosage: TABLET;ORAL; SOLUTION;ORAL; CAPSULE;ORAL
NORVIR family patents
2. Norvir patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5541206 | ABBOTT | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
| US5948436 | ABBOTT | Pharmaceutical composition |
Sep, 2013
(10 years ago) | |
|
US5541206 (Pediatric) | ABBOTT | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
|
US5948436 (Pediatric) | ABBOTT | Pharmaceutical composition |
Mar, 2014
(10 years ago) | |
| US5635523 | ABBOTT | Retroviral protease inhibiting compounds |
Jun, 2014
(9 years ago) | |
| US5648497 | ABBOTT | Retroviral protease inhibiting compounds |
Jul, 2014
(9 years ago) | |
|
US5635523 (Pediatric) | ABBOTT | Retroviral protease inhibiting compounds |
Dec, 2014
(9 years ago) | |
|
US5648497 (Pediatric) | ABBOTT | Retroviral protease inhibiting compounds |
Jan, 2015
(9 years ago) | |
Market Authorisation Date: 01 March, 1996
Treatment: Use of norvir to inhibit hiv protease or to inhibit an hiv infection; Use of ritonavir in combination with any reverse transcriptase inhibitor
Dosage: CAPSULE;ORAL
NORVIR family patents